Table 2.
Demographics and clinical characteristics (ACR criteria) for SLE patients included in the study (n = 175).
| Characteristics | SLE patients |
|---|---|
| Age | |
| Range, years | 20–78 |
| Mean ± S.D, years | 47 ± 15 |
| Disease duration | |
| Range, years | 0–57 |
| Mean ± S.D, years | 18 ± 12 |
| Gender, female, n (%) | 175 (100) |
| Thrombotic events, n (%) | 35 (20) |
| SLEDAI-2K ≥ 4, n (%) | 57 (33) |
| SDI ≥ 1, n (%) | 124 (71) |
| Increased anti-dsDNA, n (%) | 59 (34) |
| Lupus nephritis, n (%) (n = 172) | 67 (39) |
| Currently Prescribed Medication, n (%) | |
| Anticoagulation or anti-platelet (n = 174) | 40 (23) |
| Antimalarial | 127 (73) |
| Prednisone | 81 (46) |
| Lipid lowering | 26 (15) |
| Diabetes medication | 6 (3) |
| Malar rash | 127 (72.6) |
| Discoid rash | 24 (13.7) |
| Photosensitivity | 113 (64.6) |
| Oral ulcers | 108 (61.7) |
| Arthritis (≥2 peripheral joints) | 151 (86.3) |
| Serositis | 67 (38.3) |
| Neurologic disorder (seizure or psychosis) | 24 (12.0) |
| Renal disorderA | 100 (57.1) |
| eGFR (n = 160) | |
| Range, mL/min/1.73 m2 | 17–121 |
| Mean ± S.D, mL/min/1.73 m2 | 84.38 ± 24.70 |
| <60 mL/min/1.73 m2, n (%) | 26 (16.3) |
| Hematologic disorderB | 155 (88.6) |
| Immunologic disorderC | 159 (90.9) |
| Anti-nuclear antibodies (ANA) | 170 (97.1) |
| American College of Rheumatology criteria (ACR) score | |
| Range | 03-Nov |
| Mean ± S.D | 6.83 ± 1.62 |
A>0.5 g per day of protein in urine or cellular cast or end-stage renal disease.
BHemolytic anemia (low red blood cell count) or leukopenia (White blood cells < 4000/µl), lymphopenia (<100 000/µl) in the absence of offending drug.
CPositive anti-Smith, anti-dsDNA, antiphospholipid antibody and/or false positive serological test for syphilis.
eGFR: estimated glomerular filtration test.